Interleukin 6 mediates production of interleukin 10 in metastatic melanoma

Cancer Immunology, Immunotherapy

Volumn 61, Issue 2, 2012, Pages 145-155

  Terai, Mizue ^a,b   Eto, Masumi ^b   Young, Garbo D ^b   Berd, David ^c   Mastrangelo, Michael J ^b   Tamura, Yutaka ^a   Harigaya, Kenichi ^a   Sato, Takami ^a,b  

^a CHIBA UNIVERSITY   (Japan)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c Cancer Treatment Center of America   (United States)

Author keywords

IL 10; IL 6; Melanoma; Metastasis; STAT3

Indexed keywords

1,2,3,4,5,6 HEXABROMOCYCLOHEXANE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 3 (3,5 DIBROMO 4 HYDROXYBENZYLIDENE) 1,3 DIHYDRO 5 IODO 2 INDOLONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; H 1152; INTERLEUKIN 10; INTERLEUKIN 6; JANUS KINASE INHIBITOR; LIPOPOLYSACCHARIDE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PYRDONE 6; RAPAMYCIN; RHO KINASE INHIBITOR; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MELANOMA; MELANOMA CELL; METASTASIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTIBODIES, BLOCKING; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; JANUS KINASES; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MAP KINASE SIGNALING SYSTEM; MELANOMA; NEOPLASM METASTASIS; PHOSPHORYLATION; RNA, SMALL INTERFERING; SKIN NEOPLASMS; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTIONAL ACTIVATION;

EID: 84856693628     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1084-5     Document Type: Article

References (35)

1. MP Colombo A Mantovani 2005 Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion Cancer Res 65 9113 9116 16230363 10.1158/0008-5472.CAN-05-2714 1:CAS:528:DC%2BD2MXhtFWmurfO (Pubitemid 41507968)
2. DI Gabrilovich HL Chen KR Girgis, et al. 1996 Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells Nat Med 2 1096 1103 8837607 10.1038/nm1096-1096 1:CAS:528:DyaK28Xmt1Wnu7o%3D (Pubitemid 26338628)
3. KW Moore A O'Garra R de Waal Malefyt P Vieira TR Mosmann 1993 Interleukin-10 Annu Rev Immunol 11 165 190 8386517 10.1146/annurev.iy.11.040193. 001121 1:CAS:528:DyaK3sXktVKmu7o%3D (Pubitemid 23115005)
4. K Asadullah W Sterry HD Volk 2003 Interleukin-10 therapy-review of a new approach Pharmacol Rev 55 241 269 12773629 10.1124/pr.55.2.4 1:CAS:528:DC%2BD3sXltVSgtbk%3D (Pubitemid 36666048)
5. S Pestka CD Krause D Sarkar MR Walter Y Shi PB Fisher 2004 Interleukin-10 and related cytokines and receptors Annu Rev Immunol 22 929 979 15032600 10.1146/annurev.immunol.22.012703.104622 1:CAS:528:DC%2BD2cXktlOgsbg%3D (Pubitemid 38680445)
6. EC Lattime MJ Mastrangelo O Bagasra W Li D Berd 1995 Expression of cytokine mRNA in human melanoma tissues Cancer Immunol Immunother 41 151 156 7553683 10.1007/BF01521340 1:CAS:528:DyaK2MXpslWisLY%3D
7. T Sato P McCue K Masuoka, et al. 1996 Interleukin 10 production by human melanoma Clin Cancer Res 2 1383 1390 9816311 1:STN:280:DyaK1M%2FjsFWmuw%3D%3D (Pubitemid 26299438)
8. J Kim RL Modlin RL Moy, et al. 1995 IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response J Immunol 155 2240 2247 7636270 1:CAS:528:DyaK2MXnsVShsLo%3D
9. J Ordemann CA Jacobi C Braumann W Schwenk HD Volk JM Muller 2002 Immunomodulatory changes in patients with colorectal cancer Int J Colorectal Dis 17 37 41 12018452 10.1007/s003840100338 1:STN:280:DC%2BD383nslGlsg%3D%3D (Pubitemid 41398989)
10. B Knoefel K Nuske T Steiner, et al. 1997 Renal cell carcinomas produce IL-6, IL-10, IL-11, and TGF-beta 1 in primary cultures and modulate T lymphocyte blast transformation J Interferon Cytokine Res 17 95 102 9058315 10.1089/jir.1997.17.95 1:CAS:528:DyaK2sXhsVWqurw%3D (Pubitemid 27100287)
11. AR Green VL Green MC White V Speirs 1997 Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identification of interleukin-8 as a potential regulatory factor in breast tumours Int J Cancer 72 937 941 9378554 10.1002/(SICI)1097-0215(19970917)72:6<937::AID-IJC3>3.0. CO;2-Q 1:CAS:528:DyaK2sXmsFWlsL4%3D (Pubitemid 27433554)
12. W Dummer JC Becker A Schwaaf M Leverkus T Moll EB Brocker 1995 Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma Melanoma Res 5 67 68 7734958 10.1097/00008390-199502000-00008 1:STN:280:DyaK2M3lt1yitg%3D%3D
13. A Nacinovic-Duletic S Stifter S Dvornik Z Skunca N Jonjic 2008 Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma Int J Lab Hematol 30 230 239 18479302 10.1111/j.1751-553X.2007.00951.x 1:STN:280:DC%2BD1czhslegsA%3D%3D (Pubitemid 351695395)
14. N Guney HO Soydinc M Basaran, et al. 2009 Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin's lymphoma Asian Pac J Cancer Prev 10 669 674 19827892
15. MY Mapara M Sykes 2004 Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance J Clin Oncol 22 1136 1151 15020616 10.1200/JCO.2004.10.041 1:CAS:528:DC%2BD2cXptlCku7c%3D (Pubitemid 41095048)
16. D Berd T Sato HC Maguire Jr J Kairys MJ Mastrangelo 2004 Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine J Clin Oncol 22 403 415 14691123 10.1200/JCO.2004.06.043 1:CAS:528:DC%2BD2cXptlCrsrw%3D (Pubitemid 41079768)
17. D Berd HC Maguire Jr LM Schuchter, et al. 1997 Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases J Clin Oncol 15 2359 2370 9196151 1:STN:280:DyaK2szjvFGmsA%3D%3D (Pubitemid 27251139)
18. D Berd HC Maguire Jr MJ Mastrangelo 1986 Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide Cancer Res 46 2572 2577 3697996 1:STN:280:DyaL287ovFGkug%3D%3D (Pubitemid 16120733)
19. G Galizia M Orditura C Romano, et al. 2002 Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery Clin Immunol 102 169 178 11846459 10.1006/clim.2001.5163 1:CAS:528:DC%2BD38XisFWmtLk%3D (Pubitemid 34171516)
20. S Negrier D Perol C Menetrier-Caux, et al. 2004 Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6-from the Groupe Francais d'Immunotherapie J Clin Oncol 22 2371 2378 15197198 10.1200/JCO.2004.06.121 1:CAS:528:DC%2BD2cXpsVWlurg%3D (Pubitemid 41115394)
21. C Porta M De Amici S Quaglini, et al. 2008 Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma Ann Oncol 19 353 358 17962206 10.1093/annonc/mdm448 1:STN:280:DC%2BD1c%2Fotlemuw%3D%3D (Pubitemid 351201719)
22. R Mouawad A Benhammouda O Rixe, et al. 1996 Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden Clin Cancer Res 2 1405 1409 9816314 1:STN:280:DyaK1M%2FjsFWlsA%3D%3D (Pubitemid 26299441)
23. T Taga M Hibi Y Hirata, et al. 1989 Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130 Cell 58 573 581 2788034 10.1016/0092-8674(89)90438-8 1:CAS:528:DyaL1MXlsFWksLg%3D (Pubitemid 19203542)
24. A Mackiewicz H Schooltink PC Heinrich S Rose-John 1992 Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins J Immunol 149 2021 2027 1381393 1:CAS:528:DyaK3sXitVKrug%3D%3D
25. JW Oh M Revel J Chebath 1996 A soluble interleukin 6 receptor isolated from conditioned medium of human breast cancer cells is encoded by a differentially spliced mRNA Cytokine 8 401 409 8726669 10.1006/cyto.1996.0055 1:CAS:528:DyaK28XjtFOmtL4%3D (Pubitemid 26163110)
26. G Muller-Newen A Kuster U Hemmann, et al. 1998 Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses J Immunol 161 6347 6355 9834125 1:CAS:528:DyaK1cXnslCqsbs%3D (Pubitemid 28536011)
27. LA Winston T Hunter 1995 JAK2, Ras, and Raf are required for activation of extracellular signal-regulated kinase/mitogen-activated protein kinase by growth hormone J Biol Chem 270 30837 30840 8537333 10.1074/jbc.270.52.30837 1:CAS:528:DyaK28XivFSmug%3D%3D (Pubitemid 26012161)
28. T Taga T Kishimoto 1997 Gp130 and the interleukin-6 family of cytokines Annu Rev Immunol 15 797 819 9143707 10.1146/annurev.immunol.15.1.797 1:CAS:528:DyaK2sXisVGitr8%3D (Pubitemid 27169299)
29. PC Heinrich I Behrmann S Haan HM Hermanns G Muller-Newen F Schaper 2003 Principles of interleukin (IL)-6-type cytokine signalling and its regulation Biochem J 374 1 20 12773095 10.1042/BJ20030407 1:CAS:528:DC%2BD3sXmtF2hurs%3D (Pubitemid 37046923)
30. M Lucas X Zhang V Prasanna DM Mosser 2005 ERK activation following macrophage FcgammaR ligation leads to chromatin modifications at the IL-10 locus J Immunol 175 469 477 15972681 1:CAS:528:DC%2BD2MXltlymsrc%3D (Pubitemid 40884351)
31. MS Brose P Volpe M Feldman, et al. 2002 BRAF and RAS mutations in human lung cancer and melanoma Cancer Res 62 6997 7000 12460918 1:CAS:528: DC%2BD38XpsVahsbo%3D (Pubitemid 35424092)
32. PT Wan MJ Garnett SM Roe, et al. 2004 Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 116 855 867 15035987 10.1016/S0092-8674(04)00215-6 1:CAS:528:DC%2BD2cXivVyksLw%3D (Pubitemid 38410730)
33. J Goodall C Wellbrock TJ Dexter K Roberts R Marais CR Goding 2004 The Brn-2 transcription factor links activated BRAF to melanoma proliferation Mol Cell Biol 24 2923 2931 15024080 10.1128/MCB.24.7.2923-2931.2004 1:CAS:528:DC%2BD2cXis1emtro%3D (Pubitemid 38381281)
34. H Sumimoto F Imabayashi T Iwata Y Kawakami 2006 The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells J Exp Med 203 1651 1656 16801397 10.1084/jem.20051848 1:CAS:528:DC%2BD28XntVCgsrg%3D (Pubitemid 44036269)
35. M Terai Y Tamura V Alexeev, et al. 2009 Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: immunoadhesins for human IL-10 with therapeutic potential Cancer Immunol Immunother 58 1307 1317 19142637 10.1007/s00262-008- 0644-9 1:CAS:528:DC%2BD1MXmsVGisr0%3D